Myomo, Inc. (MYO)

Myomo, Inc.'s stock price experienced a significant decline of 86.38% from March 27, 2025, to March 26, 2026. Key events impacting the stock include the Q3 2025 financial results, where Myomo reported revenue growth but a net loss. The Q4 and full-year 2025 financial results showed increased revenue and record MyoPro orders, but also a widened net loss. Myomo announced a contract with Elevance Health and an analyst price target decrease also occurred.

Myomo's demand seasonality analysis suggests that March may not be an ideal month for investment, while January has shown the highest probability of positive returns. Despite these monthly fluctuations, Myomo has demonstrated consistent revenue growth and a consistently upward trending reimbursement pipeline. The company is strategically focusing on the Medicare market, which is expected to significantly boost revenue.

Myomo, Inc. is a wearable medical robotics company specializing in myoelectric orthotics for individuals with neuromuscular disorders and upper-limb paralysis. Their core product, MyoPro, is a powered upper-limb orthosis that supports and restores function to weakened or paralyzed arms. The company offers various versions of MyoPro, along with virtual training platforms and post-delivery follow-up programs. Myomo distributes its products directly to patients, billing their insurance companies, and also sells through O&P providers, the VA, and international distributors.

Myomo, Inc. has a geographic footprint that includes the United States, Germany, and other international markets. The company delivers MyoPro devices in the U.S. and Canada, and has CE Mark approval and O&P distribution partners in Europe. European operations are managed from Germany. The company has also expanded its global reach through patent awards in China, Hong Kong, and Japan. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals located across the U.S.

Myomo's brand reputation has been affected by challenges related to marketing effectiveness and lead conversion rates. Changes in social media algorithms limited the access of health-related information, leading to less effective ad spending and a drop in leads. The company also faced issues with insurance reimbursement. Myomo held an Investor Day to address these challenges and lowered its 2025 revenue guidance.

Myomo, Inc. is owned by a mix of institutional shareholders, individual investors, and company insiders. Major institutional owners include Rosalind Advisors, Inc., BlackRock, Inc., and Vanguard Group Inc. Key individual and insider owners include Paul R. Gudonis, Mgc Venture Partners 2013 LP, Steve Sanghi, and Thomas F. Kirk.